Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage
- 17 January 2017
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 46 (7) , 2165-2173
Abstract
A light-activated prodrug delivers both a DNA damaging metal center and a cytochrome P450 inhibitor to prevent drug resistance.Keywords
Funding Information
- Fundación Séneca (19020/FPI/13)
- National Institute of General Medical Sciences (5R01GM107586)
- American Cancer Society (RSG-13-079-01-CDD)
- Ministerio de Economía y Competitividad
This publication has 60 references indexed in Scilit:
- Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancerCancer Medicine, 2012
- Design of photoactive ruthenium complexes to study electron transfer and proton pumping in cytochrome oxidaseBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2012
- Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001Nature, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Three Clusters of Conformational States in P450cam Reveal a Multistep Pathway for Closing of the Substrate Access Channel,Biochemistry, 2010
- Role of cytochrome P450 in drug interactionsNutrition & Metabolism, 2008
- Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug developmentBioorganic & Medicinal Chemistry, 2007
- Mitochondrial P450sChemico-Biological Interactions, 2006
- Cytochrome P450s and other enzymes in drug metabolism and toxicityThe AAPS Journal, 2006
- Conformational States of Cytochrome P450cam Revealed by Trapping of Synthetic Molecular WiresJournal of Molecular Biology, 2004